New combo therapy targets tough cancers
NCT ID NCT05438420
First seen Feb 25, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study tests a new drug called Q702 combined with pembrolizumab (an immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and shrinks tumors. About 120 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, South Korea
-
CHA Bundang Medical Center
Seongnam-si, South Korea
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital
Seoul, South Korea
-
University of Southern California
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.